|Awarded On||February 16, 2022|
|Title||RIP PROTACs as a Novel Immunotherapy Sensitizer to Treat Colorectal Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Jin Wang|
Colorectal cancer (CRC) is the second leading cause of cancer death with an estimated 8.7% of cancer-related deaths and about 149,500 new cases of CRC diagnosed in 2021. Although overall mortality from CRC continues to decline, survival remains poor for advanced disease. While chemotherapy is still the mainstay to treat CRC, cancer immunotherapies, immune checkpoint blockades (ICBs) in particular, have achieved unprecedented clinical responses and are revolutionizing cancer treatments. Despite of the tremendous success of cancer immunotherapies, it remains unclear why only a subset of individuals respond to treatment and how to turn non-responders to become responsive. Many combination trial...